# Lilly: Taltz plus Zepbound gave ACR50 in 43.7% vs 15.7% on Taltz alone at one year, Phase 3b

- Published: 2026-11-12 05:18 UTC
- Section: Life & Health › Medicine
- Tags: TOGETHER-PsA, Taltz and Zepbound, psoriatic arthritis and obesity, ACR50 at one year, ixekizumab tirzepatide, Phase 3b trial, Eli Lilly, ACR Convergence 2026
- URL: https://realtech.media/news/rt-42ffbb044987a7eb17339cdd_lilly_taltz_plus/

**In the 271-patient TOGETHER-PsA Phase 3b trial, adding Zepbound to Taltz in psoriatic arthritis with obesity kept its advantage in disease activity through Week 52.**

![Lilly: Taltz plus Zepbound gave ACR50 in 43.7% vs 15.7% on Taltz alone at one year, Phase 3b](https://realtech.media/media/2026/11/d20806ccc8c6703b.jpg)
*Littlewill1166, Wikimedia Commons, CC BY-SA 4.0*

Eli Lilly and Company announced on Nov. 11, 2026 detailed 52-week results of the TOGETHER-PsA Phase 3b trial, according to prnewswire.com. The study compared concomitant Taltz (ixekizumab) and Zepbound (tirzepatide) with Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition [1]. At one year, 43.7% of patients on the combination achieved ACR50 versus 15.7% on Taltz alone [1]. The data were presented at ACR Convergence 2026 and published in Arthritis & Rheumatology [1].

## Trial design and Week 36 results

TOGETHER-PsA (NCT06588296) is a randomized, multicenter, assessor-blinded, open-label study. A total of 271 participants were randomized 1:1 to Taltz alone or Taltz together with Zepbound, both given subcutaneously [1]. Patients in both arms received counseling on a reduced-calorie diet and increased physical activity. Mean baseline BMI was 37.6 [1].

The primary endpoint was the proportion of participants achieving both ACR50 and at least 10% weight reduction at Week 36. As previously reported, the combination met the primary and all key secondary endpoints for statistically significant superiority over Taltz alone at that time point [1].

## Week 52 findings

ACR50 reflects at least a 50% reduction in PsA disease activity. A greater proportion of patients reached ACR50 in the combination arm as early as Week 4, before clinically meaningful weight loss was observed, the company reported [1]. Patient-reported outcomes, including physical function and fatigue, were maintained or further improved from Week 36 to Week 52 with the combination [1]. The combination was also associated with improvements in BMI, body weight, systolic blood pressure, glucose, HbA1c, triglycerides and total cholesterol compared with Taltz alone [1].

The Week 52 analyses are pre-specified exploratory objectives without multiplicity control, and comparisons between time points are descriptive [1].

Adverse events in the combination arm were generally mild to moderate and consistent with the known safety profile of each medicine [1]. Those occurring in at least 5% of participants included nausea, diarrhea, constipation, injection site reactions, vomiting, urinary tract infections, sinusitis, dizziness and headache. In the Taltz arm they were injection site reactions, upper respiratory tract infections, arthralgia and diarrhea [1].

According to the company, about 65% of people with PsA in the U.S. also have obesity or overweight with at least one weight-related comorbidity [1].

## Sources

1. [prnewswire.com](https://www.prnewswire.com/news-releases/new-phase-3b-data-on-lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-showed-improved-and-durable-efficacy-patient-reported-and-metabolic-outcomes-at-one-year-in-adults-with-psoriatic-arthritis-and-obesity-302935708.html)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-42ffbb044987a7eb17339cdd_lilly_taltz_plus/